A psychedelics startup has a big vision. Investors aren’t buying it.

Awakn Life Science’s ketamine therapy for alcohol use disorder is promising. Will it be profitable?

Awakn’s London clinic

British psychiatrist Ben Sessa believes fervently in psychedelic medicines. They are “likely to change the whole paradigm of psychiatry,” says Sessa, who a co-founder and head of…